Although there are no available prospective data on the efficacy of ICI monotherapy versus ICI plus chemotherapy in patients with low tumor PD-L1 expression levels (TPS of <50%), it is suggested that more upcoming clinical trials could be conducted to discuss the efficacy separately according to the expression of PD-1/PD-L1 [86]. The gene discussed is PDCD1; the disease is neoplasm.